Advertisement
Advertisement
U.S. markets close in 5 hours 28 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Schmitt Industries, Inc. (SMIT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.8300-0.0200 (-0.52%)
As of 9:30AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close3.8500
Open3.7000
Bid3.6800 x 1000
Ask3.8900 x 800
Day's Range3.8300 - 3.8300
52 Week Range3.6100 - 8.3800
Volume37
Avg. Volume57,495
Market Cap14.708M
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-2.4680
Earnings DateApr 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 23, 1994
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SMIT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Schmitt Industries, Inc.
    Analyst Report: Danaher CorporationIn 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
Advertisement
Advertisement